Cargando…
Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer
BACKGROUND: Bevacizumab improves progression free survival (PFS) and overall survival (OS) in metastatic colorectal cancer patients however currently there are no biomarkers that predict response to this treatment. The aim of this study was to assess if differential protein expression can differenti...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289341/ https://www.ncbi.nlm.nih.gov/pubmed/25428203 http://dx.doi.org/10.1186/1471-2407-14-887 |
_version_ | 1782352097568620544 |
---|---|
author | Martin, Petra Noonan, Sinead Mullen, Michael P Scaife, Caitriona Tosetto, Miriam Nolan, Blathnaid Wynne, Kieran Hyland, John Sheahan, Kieran Elia, Giuliano O’Donoghue, Diarmuid Fennelly, David O’Sullivan, Jacintha |
author_facet | Martin, Petra Noonan, Sinead Mullen, Michael P Scaife, Caitriona Tosetto, Miriam Nolan, Blathnaid Wynne, Kieran Hyland, John Sheahan, Kieran Elia, Giuliano O’Donoghue, Diarmuid Fennelly, David O’Sullivan, Jacintha |
author_sort | Martin, Petra |
collection | PubMed |
description | BACKGROUND: Bevacizumab improves progression free survival (PFS) and overall survival (OS) in metastatic colorectal cancer patients however currently there are no biomarkers that predict response to this treatment. The aim of this study was to assess if differential protein expression can differentiate patients who respond to chemotherapy and bevacizumab, and to assess if select proteins correlate with patient survival. METHODS: Pre-treatment serum from patients with metastatic colorectal cancer (mCRC) treated with chemotherapy and bevacizumab were divided into responders and nonresponders based on their progression free survival (PFS). Serum samples underwent immunoaffinity depletion and protein expression was analysed using two-dimensional difference gel electrophoresis (2D-DIGE), followed by LC-MS/MS for protein identification. Validation on selected proteins was performed on serum and tissue samples from a larger cohort of patients using ELISA and immunohistochemistry, respectively (n = 68 and n = 95, respectively). RESULTS: 68 proteins were identified following LC-MS/MS analysis to be differentially expressed between the groups. Three proteins (apolipoprotein E (APOE), angiotensinogen (AGT) and vitamin D binding protein (DBP)) were selected for validation studies. Increasing APOE expression in the stroma was associated with shorter progression free survival (PFS) (p = 0.0001) and overall survival (OS) (p = 0.01), DBP expression (stroma) was associated with shorter OS (p = 0.037). Increasing APOE expression in the epithelium was associated with a longer PFS and OS, and AGT epithelial expression was associated with a longer PFS (all p < .05). Increasing serum AGT concentration was associated with shorter OS (p = 0.009). CONCLUSIONS: APOE, DBP and AGT identified were associated with survival outcomes in mCRC patients treated with chemotherapy and bevacizumab. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2407-14-887) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4289341 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42893412015-01-11 Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer Martin, Petra Noonan, Sinead Mullen, Michael P Scaife, Caitriona Tosetto, Miriam Nolan, Blathnaid Wynne, Kieran Hyland, John Sheahan, Kieran Elia, Giuliano O’Donoghue, Diarmuid Fennelly, David O’Sullivan, Jacintha BMC Cancer Research Article BACKGROUND: Bevacizumab improves progression free survival (PFS) and overall survival (OS) in metastatic colorectal cancer patients however currently there are no biomarkers that predict response to this treatment. The aim of this study was to assess if differential protein expression can differentiate patients who respond to chemotherapy and bevacizumab, and to assess if select proteins correlate with patient survival. METHODS: Pre-treatment serum from patients with metastatic colorectal cancer (mCRC) treated with chemotherapy and bevacizumab were divided into responders and nonresponders based on their progression free survival (PFS). Serum samples underwent immunoaffinity depletion and protein expression was analysed using two-dimensional difference gel electrophoresis (2D-DIGE), followed by LC-MS/MS for protein identification. Validation on selected proteins was performed on serum and tissue samples from a larger cohort of patients using ELISA and immunohistochemistry, respectively (n = 68 and n = 95, respectively). RESULTS: 68 proteins were identified following LC-MS/MS analysis to be differentially expressed between the groups. Three proteins (apolipoprotein E (APOE), angiotensinogen (AGT) and vitamin D binding protein (DBP)) were selected for validation studies. Increasing APOE expression in the stroma was associated with shorter progression free survival (PFS) (p = 0.0001) and overall survival (OS) (p = 0.01), DBP expression (stroma) was associated with shorter OS (p = 0.037). Increasing APOE expression in the epithelium was associated with a longer PFS and OS, and AGT epithelial expression was associated with a longer PFS (all p < .05). Increasing serum AGT concentration was associated with shorter OS (p = 0.009). CONCLUSIONS: APOE, DBP and AGT identified were associated with survival outcomes in mCRC patients treated with chemotherapy and bevacizumab. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2407-14-887) contains supplementary material, which is available to authorized users. BioMed Central 2014-11-27 /pmc/articles/PMC4289341/ /pubmed/25428203 http://dx.doi.org/10.1186/1471-2407-14-887 Text en © Martin et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Martin, Petra Noonan, Sinead Mullen, Michael P Scaife, Caitriona Tosetto, Miriam Nolan, Blathnaid Wynne, Kieran Hyland, John Sheahan, Kieran Elia, Giuliano O’Donoghue, Diarmuid Fennelly, David O’Sullivan, Jacintha Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer |
title | Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer |
title_full | Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer |
title_fullStr | Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer |
title_full_unstemmed | Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer |
title_short | Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer |
title_sort | predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289341/ https://www.ncbi.nlm.nih.gov/pubmed/25428203 http://dx.doi.org/10.1186/1471-2407-14-887 |
work_keys_str_mv | AT martinpetra predictingresponsetovascularendothelialgrowthfactorinhibitorandchemotherapyinmetastaticcolorectalcancer AT noonansinead predictingresponsetovascularendothelialgrowthfactorinhibitorandchemotherapyinmetastaticcolorectalcancer AT mullenmichaelp predictingresponsetovascularendothelialgrowthfactorinhibitorandchemotherapyinmetastaticcolorectalcancer AT scaifecaitriona predictingresponsetovascularendothelialgrowthfactorinhibitorandchemotherapyinmetastaticcolorectalcancer AT tosettomiriam predictingresponsetovascularendothelialgrowthfactorinhibitorandchemotherapyinmetastaticcolorectalcancer AT nolanblathnaid predictingresponsetovascularendothelialgrowthfactorinhibitorandchemotherapyinmetastaticcolorectalcancer AT wynnekieran predictingresponsetovascularendothelialgrowthfactorinhibitorandchemotherapyinmetastaticcolorectalcancer AT hylandjohn predictingresponsetovascularendothelialgrowthfactorinhibitorandchemotherapyinmetastaticcolorectalcancer AT sheahankieran predictingresponsetovascularendothelialgrowthfactorinhibitorandchemotherapyinmetastaticcolorectalcancer AT eliagiuliano predictingresponsetovascularendothelialgrowthfactorinhibitorandchemotherapyinmetastaticcolorectalcancer AT odonoghuediarmuid predictingresponsetovascularendothelialgrowthfactorinhibitorandchemotherapyinmetastaticcolorectalcancer AT fennellydavid predictingresponsetovascularendothelialgrowthfactorinhibitorandchemotherapyinmetastaticcolorectalcancer AT osullivanjacintha predictingresponsetovascularendothelialgrowthfactorinhibitorandchemotherapyinmetastaticcolorectalcancer |